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A
 
BSTRACT
Background:
 
Although 
 
β
 
-adrenergic receptor ago-
nists inhibit antigen-induced release of histamine,
leukotrienes and prostaglandin D
 
2
 
 from human lung
fragments, dispersed human lung mast cells and human
skin mast cells, subcellular mechanisms for the inhibi-
tion of histamine release by 
 
β
 
-adrenergic receptor
agonists are not well delineated. The aim of the present
study was to investigate the inhibitory mechanisms of
 
β
 
-adrenergic receptor agonists for human mast cell
histamine release using human cultured mast cells.
 
Methods:
 
Human mast cells were obtained by cultur-
ing umbilical cord blood CD34
 
+
 
 cells in the presence
of stem cell factor and interleukin-6. Cultured mast
cells were sensitized with human myeloma IgE and
stimulated with antihuman IgE.
 
Results:
 
Stimulation of mast cells induced the eleva-
tion of intracellular cytosolic free Ca
 
2+
 
 concentrations
([Ca
 
2+
 
]
 
i
 
) and the translocation of protein kinase C
(PKC) from the cytosol to the cell membrane, followed
by the release of stored histamine. Isoproterenol, sal-
butamol and dibutyryl cAMP inhibited both the hista-
mine release and PKC translocation, whereas they
failed to affect the elevation of [Ca
 
2+
 
]
 
i
 
. H-89, a protein
kinase A (PKA) inhibitor, abrogated the inhibition.
 
Conclusions:
 
The present results suggest that PKA
activation induced by 
 
β
 
-adrenergic receptor agonists
plays a crucial role in inhibiting IgE-mediated hista-
mine release from human cultured mast cells through
suppressing PKC translocation.
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I
 
NTRODUCTION
 
β
 
-Adrenergic receptor agonists possess a potent relaxing
effect on the bronchial smooth muscle and have been
widely used clinically as bronchodilators to prevent or
relieve asthma attacks. However, it is also well known
that 
 
β
 
-adrenergic receptor agonists show potent anti-
inflammatory effects in basic experiments. 
 
β
 
-Adrenergic
receptor agonists inhibit antigen-induced release of
histamine, leukotrienes and prostaglandin D
 
2
 
 from
human lung fragments,
 
1–6
 
 dispersed human lung mast
cells
 
7–10
 
 and human skin mast cells.
 
9
 
 The inhibition is far
more potent than that produced by disodium cromogly-
cate, one of the typical mast cell stabilizers.
 
1,2,5,7
 
 How-
ever, the subcellular mechanisms for the inhibition of
histamine release by 
 
β
 
-adrenergic receptor agonists are
not well delineated and the contribution of the anti-
inflammatory effects of 
 
β
 
-adrenergic receptor agonists to
their clinical efficacy for asthma treatment has not been
recognized.
In contrast, human cultured mast cells (HCMC) are a
useful tool to investigate biochemical events during their
activation.
 
11–14
 
 Previously, we reported that IgE-dependent
activation of human cultured mast cells induced the
elevation of cytosolic free Ca
 
2+
 
 concentrations and
translocation of protein kinase C (PKC) from the cytosol
to the cell membrane, followed by the release of stored
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histamine.
 
13,14
 
 The importance of Ca
 
2+
 
 and PKC signal-
ing for mast cell histamine release has also been well
documented by many investigators.
 
15–19
 
In the present study, we examined the effects of 
 
β
 
-
adrenergic receptor agonists on Ca
 
2+
 
 and PKC signaling
upon stimulation of HCMC to elucidate the inhibitory
mechanism for histamine release.
 
M
 
ETHODS
 
Antibodies and reagents
 
Human myeloma IgE (Chemicon International, Temecula,
CA, USA) and antihuman IgE (anti-IgE; DAKO, Glos-
trup, Denmark) were used for sensitization and stimula-
tion of mast cells, respectively. Isoproterenol, salbutamol
and dibutyryl cAMP (Bt
 
2
 
-cAMP) were purchased from
Sigma-Aldrich (St Louis, MO, USA). H-89, a protein
kinase A (PKA) inhibitor,
 
20,21
 
 was obtained from
Calbiochem-Novabiochem (San Diego, CA, USA). 
 
β
 
-
Adrenergic receptor agonists and Bt
 
2
 
-cAMP were added
to cells 10 min before anti-IgE stimulation and H-89 was
added 5 min before drug treatment.
 
Mast cells
 
Human mast cells were obtained by culturing umbilical
cord blood mononuclear cells according to methods
described previously, with some modifications.
 
22,23
 
 Briefly,
mononuclear cells were separated from heparinized
umbilical cord blood by density gradient centrifugation
using Lymphocyte Separation Medium (ICN Biomedi-
cals, Aurora, OH, USA). Then, CD34
 
+
 
 cells were purified
from the mononuclear cell fraction by using a CD34
 
+
 
progenitor cell isolation kit (Miltenyi Biotec, Bergisch,
Germany) and Magnetic Cell Sorting System (Miltenyi
Biotec). Purified CD34
 
+
 
 cells were cultured in 
 
α
 
-minimum
essential medium (Gibco-BRL Laboratories, Gland Island,
NY, USA) supplemented with 15% fetal bovine serum
(Filtron, Brooklyn, NSW, Australia) in the presence of
80 ng/mL human recombinant stem cell factor (Kirin
Brewery, Maebashi, Japan) and 50 ng/mL human recom-
binant interleukin (IL)-6 (Kirin Brewery). Cells were
harvested and resuspended in fresh medium weekly.
Mast cells cultured over 15 weeks were used in the
present study. Immunoperoxidase staining for tryptase
 
24
 
revealed that the cells were almost 100% positive for
tryptase.
 
Histamine release
 
Mast cells were sensitized with myeloma IgE under
incubation at 37
 
°
 
C overnight. Sensitized cells were washed
and resuspended in Tyrode’s solution (126 mmol/L
NaCl, 4 mmol/L KCl, 0.64 mmol/L NaH
 
2
 
PO
 
4
 
, 1 mmol/
L CaCl
 
2
 
, 0.6 mmol/L MgCl
 
2
 
, 0.1% glucose, 10 mmol/L
HEPES, 0.03% bovine serum albumin, pH 7.4) at a
concentration of 1 
 
×
 
 10
 
5
 
 cells/mL. Histamine release was
induced by stimulating with 4 
 
µ
 
g/mL anti-IgE for 30 min.
Histamine released into the supernatants was quantified
by a post-column derivatization method, as described
previously.
 
25,26
 
 The minimal detectable concentration of
histamine was 0.2 ng/mL. Cell-associated histamine
was extracted in the presence of perchloric acid. Total
cell-associated histamine was approximately 10 
 
µ
 
g/10
 
6
 
mast cells and 10–30% of total histamine was released
following IgE-dependent stimulation under the present
experimental conditions.
 
Measurement of intracellular cAMP levels
 
Mast cells were suspended at a concentration of
5 
 
×
 
 10
 
5
 
 cells/mL in Tyrode’s solution and were treated
with 
 
β
 
-adrenergic receptor agonists for 10 min. The cell
suspensions were frozen in liquid nitrogen and then
sonicated. The cAMP levels in the samples were meas-
ured by a cAMP enzyme-immunoassay kit (Amersham
Pharmacia Biotech, Buckinghamshire, UK).
 
27
 
 The minimal
detectable concentration was 2.0 fmol.
 
Measurement of cytosolic free Ca
 
2+
 
 
concentration
 
Fura-2AM (Microprobe, Funakoshi, Tokyo, Japan) was
loaded to sensitized mast cells. After being washed twice
with Tyrode’s solution, cells were resuspended in the
same solution at 2 
 
×
 
 10
 
6
 
 cells/mL and then stimulated
with anti-IgE at 4 
 
µ
 
g/mL. Intracellular Ca
 
2+
 
 concentra-
tions were determined with an automatic Ca
 
2+
 
 analyzer
(CAF-100; JEOL, Tokyo, Japan) at 2 min after stimula-
tion. The ratio of fura-2 signals between two excitation
waves (340 and 380 nm) was measured at 510 nm
emission.
 
Protein kinase C translocation
 
Sensitized mast cells (1 
 
×
 
 10
 
6
 
 cells/tube) were stimulated
with 4 
 
µ
 
g/mL anti-IgE for 10 min. After centrifugation,
the cells were scraped with 1 mL buffer A (20 mmol/L
 β
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Tris-HCl, pH 7.5, containing 5 mmol/L EDTA, 10 mmol/L
EGTA, 50 mg/mL phenylmethylsulfonyl fluoride, 10 mmol/L
benzamidine, 0.3% v/v 
 
β
 
-mercaptoethanol), sonicated
for 30 s and then centrifuged at 100 000 
 
g
 
 for 60 min
at 4
 
°
 
C. The pellet was resonicated in buffer A containing
1% IGEPAL CA-630 (Sigma-Aldrich) for 20 s. The reson-
icated pellet (membrane fraction) was used for assaying
PKC specific activity (pmol transferred phosphate/min
per 10
 
7
 
 cells) using a PKC enzyme-assay kit (Amersham,
Buckinghamshire, England). Protein kinase C activity in
the cytosol fraction of resting mast cells was approxi-
mately 5 pmol/min per 10
 
7
 
 cells, which was reduced to
two-thirds at 10 min after anti-IgE stimulation. Mem-
brane fraction PKC activity in resting cells was approxi-
mately 0.5 pmol/min per 10
 
7
 
 cells and increased
approximately fourfold 10 min after stimulation.
 
R
 
ESULTS
 
Inhibition of histamine release and elevation 
of intracellular cAMP levels by 
 
β
 
-adrenergic 
receptor agonists
 
Isoproterenol and salbutamol concentration-dependently
inhibited IgE-mediated histamine release from human
cultured mast cells and increased intracellular cAMP
levels (Fig. 1). Anti-IgE had no effect on intracellular
cAMP levels (data not shown). Isoproterenol was appar-
ently more potent than salbutamol.
 
Effects of 
 
β
 
-adrenergic receptor agonists on 
Ca
 
2+
 
 and PKC signaling
 
Anti-IgE stimulation elevates the cytosolic free Ca
 
2+
 
concentration of cultured mast cells. It peaks at 2 min
after stimulation and gradually declines thereafter.
 
13
 
 As
shown in Fig. 2, preincubation of cultured mast cells with
1 
 
µ
 
mol/L β-adrenergic receptor agonists and 1 mmol/L
Bt2-cAMP failed to affect the elevation of cytosolic free
Ca2+ concentrations at 2 min after stimulation.
When cultured mast cells are stimulated with anti-IgE,
the PKC activity in the cytosol decreases and that in the
membrane fractions increases. The PKC translocation
reaches a plateau at 10 min after stimulation.13 As shown
in Fig. 3, isoproterenol at concentrations of 0.001–1 µmol/L,
and salbutamol, at concentrations of 0.01–1 µmol/L,
potently inhibited the increase in PKC activity in mem-
brane fractions. At 1 mmol/L, Bt2-cAMP also inhibited the
increase mildly.
Effects of H-89 on β-adrenergic receptor 
agonist-induced inhibition of histamine 
release and PKC translocation
The effects of H-89, a PKA inhibitor, on the inhibition of
histamine release caused by β-adrenergic receptor ago-
nists and Bt2-cAMP were investigated. As shown in
Fig. 4, 0.01 µmol/L isoproterenol, 0.1 µmol/L salbuta-
mol and 1 mmol/L Bt2-cAMP potently inhibited hista-
mine release. At concentrations of 0.1–3 µmol/L, H-89
Fig. 1 Effects of isoproterenol and salbutamol on (a) histamine release and (b) cAMP levels in human cultured mast cells. Sensitized
mast cells were incubated with the β-adrenergic receptor agonists for 10 min before anti-IgE stimulation for histamine release. Cyclic
AMP levels were examined using non-sensitized mast cells after incubation with the agonists for 10 min. Values are expressed as the
mean (±SEM) percent inhibition of control histamine release (a; n = 4) and percent enhancement of control cAMP levels (b; n = 6).
200 T KATO ET AL.
concentration-dependently attenuated the inhibition of
histamine release. We have confirmed that H-89 did
not induce histamine release at concentrations up to
10 mmol/L and had no effect on IgE-mediated hista-
mine release (data not shown).
The effects of H-89 on the inhibition of PKC transloca-
tion were investigated. Translocation of PKC activity from
the cytosol to the membrane was potently inhibited by
0.01 µmol/L isoproterenol and 0.1 µmol/L salbutamol.
At a concentration of 3 µmol/L, H-89 abrogated the inhi-
bition (Fig. 5). Protein kinase C translocation was mildly
inhibited by 1 mmol/L Bt2-cAMP and the inhibition was
attenuated by H-89 (Fig. 5).
DISCUSSION
IgE-dependent activation of HCMC induces the eleva-
tion of cytosolic free Ca2+ concentrations and transloca-
tion of PKC from the cytosol to the cell membrane,
followed by the release of stored histamine.13,14 Mast cell
histamine release is regulated by Ca2+ and PKC signal-
ing pathways, both of which are required for adequate
histamine release.13–19 In the present study, we indicated
that β-adrenergic receptor agonists inhibit histamine
release and PKC translocation without affecting the
elevation in intracellular Ca2+ concentrations in HCMC.
Furthermore, we demonstrated that PKA activation plays
a crucial role in the inhibition of IgE-mediated histamine
release from HCMC by β-adrenergic receptor agonists
through suppressing PKC translocation and activation.
Activation of β2-adrenergic receptors promotes Gs-
protein and adenylate cyclase activation, resulting in the
elevation of intracellular cAMP levels and subsequent
activation of PKA.28,29 In the present study, β-adrenergic
receptor agonists inhibited IgE-mediated histamine release
from HCMC, which was accompanied by an elevation of
intracellular cAMP levels. A positive correlation between
these two events suggests the importance of PKA activa-
tion for the inhibition of histamine release by β-adrenergic
receptor agonists. In contrast, although Ca2+ signaling is
well known to be of importance for mast cell histamine
release,13–19 β-adrenergic receptor agonists did not
affect the elevation of cytosolic free Ca2+ concentrations.
Because IgE-mediated histamine release from HCMC
depends on extracellular Ca2+,13 β-adrenergic receptor
agonists do not seem to affect Ca2+ influx. Furthermore,
we have confirmed that β-adrenergic receptor agonists
Fig. 2 Effects of (a) isoprotere-
nol, salbutamol and (b) dibutyryl
cAMP (Bt2-cAMP) on IgE-medi-
ated elevation of cytosolic free
Ca2+ concentrations in human
cultured mast cells. Sensitized and
fura-2-loaded mast cells were
incubated with the drugs for
10 min before anti-IgE stimula-
tion. Intracellular Ca2+ concentra-
tions were examined 2 min after
stimulation (). ( ), prestimula-
tion. The ratio of fura-2 signals
was measured by a Ca2+ analyzer.
Data are the mean ± SEM of three
separate experiments.
Fig. 3 Effects of isoproterenol, salbutamol and dibutyryl cAMP
(Bt2-cAMP) on IgE-mediated protein kinase C (PKC) transloca-
tion in human cultured mast cells. Sensitized mast cells were in-
cubated with the drugs for 10 min before anti-IgE stimulation.
Stimulated cells were recovered 10 min later and PKC activity
was examined. Data are the mean ± SEM of three separate ex-
periments.
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do not inhibit histamine release caused by calcium iono-
phore A23187 (T Kato et al., unpubl. obs., 1999). In
contrast, β-adrenergic receptor agonists inhibited IgE-
mediated PKC translocation, which correlated well with
the inhibition of histamine release. Inhibition of PKC
translocation was caused not only by β-adrenergic recep-
tor agonists and Bt2-cAMP, but also by forskolin (T Kato
et al., unpubl. obs., 1999). These results indicate that
β-adrenergic receptor agonists do not inhibit Ca2+ signal-
ing, but do inhibit PKC signaling in HCMC. However, it has
been reported in rodent mast cells that histamine release
caused by calcium ionophore A23187 accompanies PKC
translocation and activation.30,31 Diacylglycerol derived
from the phospholipase Cγ1 or the phospholipase D
pathways activates PKC in the presence of Ca2+ and the
role of phospholipase D in the activation of rodent mast
cells has also been reported.32 Although we need to
confirm the effects of β-adrenergic receptor agonists on
calcium ionophore A23187-induced PKC translocation,
IgE-dependent stimulation and calcium ionophore
A23187 may operate distinct mechanisms for PKC trans-
location.
Because elevation of intracellular cAMP levels causes
the activation of PKA, it seems likely that the inhibitory
Fig. 5 Effects of 3 µmol/L H-89 on the inhibition of protein
kinase C (PKC) translocation caused by isoproterenol, salbuta-
mol and dibutyryl cAMP (Bt2-cAMP). Sensitized mast cells were
incubated with the drugs for 10 min before anti-IgE stimulation.
Cells were treated with H-89 5 min prior to drug incubation.
Stimulated cells were recovered 10 min later and PKC activity
was examined ( ). (), no H-89. Values are expressed as the
percentage inhibition of the control. Data are the mean ± SEM
of three separate experiments.
Fig. 4 Effects of H-89 on the inhibition of histamine release from human cultured mast cells caused by (a) 0.01 µmol/L isoproter-
enol, (b) 0.1 µmol/L salbutamol and (c) 1 mmol/L dibutyryl cAMP (Bt2-cAMP). Sensitized mast cells were incubated with the drugs
for 10 min before anti-IgE stimulation. Cells were treated with H-89 5 min prior to drug incubation. Data are the mean ± SEM of
three separate experiments.
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effects of β-adrenergic receptor agonists on PKC signal-
ing in HCMC are mediated through PKA activation. To
confirm the role of PKA activation, we used a PKA inhibi-
tor, namely H-89.20,21 H-89 abrogated the β-adrenergic
receptor agonist-induced inhibition of histamine release
and PKC translocation in HCMC. Similar results have
been obtained when the inhibition was induced by fors-
kolin (T Kato et al., unpubl. obs., 1999). Therefore, these
results demonstrate that PKA activation plays a crucial
role in the inhibition of IgE-mediated histamine release
and PKC translocation by β-adrenergic receptor agonists
in HCMC. Although it has been reported that PKA could
inhibit phospholipase D activation in a cell-free system of
human neutrophils,33 the mechanism between the activa-
tion of PKA and the inhibition of PKC activation in HCMC
remains to be elucidated.
β-Adrenergic receptor agonists possess a potent relax-
ing effect on the bronchial smooth muscle. It has been
believed that phosphorylation of several proteins by acti-
vated PKA results in the relaxation of smooth muscles.34
However, PKA-mediated effects are only observed at
relatively high concentrations of β-adrenergic receptor
agonists, when maximum relaxation responses have
been exceeded. Kume et al. demonstrated that large-
conductance potassium channels in airway smooth
muscle cells can be opened directly by the α-subunit of
the Gs-protein,35,36 suggesting that β-adrenoceptors are
directly coupled to the potassium channels and that
β-adrenergic receptor agonists may relax airway smooth
muscle independently of an increase in cAMP. These
effects are observed at low concentrations of β-adrenergic
receptor agonists in human airways in vitro, suggesting
that this is a major mechanism of airway smooth muscle
response to β-adrenergic receptor agonists.37 Therefore,
the major mechanism of β-adrenergic receptor agonists
for inhibiting mast cell histamine release may be distinct
from that for smooth muscle relaxation and this may
explain the small contribution of the anti-inflammatory
effects of β-adrenergic receptor agonists to their efficacy
in asthma treatment.
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